Comparison of fully versus partially covered metal stents in endoscopic ultrasound-guided hepaticogastrostomy for malignant biliary obstruction (with video).

Sung Hyun Cho, Seong Je Kim, Tae Jun Song, Dongwook Oh, Dong-Wan Seo
{"title":"Comparison of fully versus partially covered metal stents in endoscopic ultrasound-guided hepaticogastrostomy for malignant biliary obstruction (with video).","authors":"Sung Hyun Cho, Seong Je Kim, Tae Jun Song, Dongwook Oh, Dong-Wan Seo","doi":"10.1111/den.14952","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) using a fully covered metal stent (FCMS) or partially covered metal stent (PCMS) is performed to manage unresectable malignant biliary obstruction (MBO) following unsuccessful endoscopic retrograde cholangiopancreatography. This study aimed to compare FCMS and PCMS for EUS-HGS in patients with MBO.</p><p><strong>Methods: </strong>We reviewed the EUS database to analyze consecutive patients with MBO who underwent EUS-HGS between November 2017 and March 2023. We performed a 1:1 matching using propensity score matching based on potential confounding factors. Stent patency, technical success, clinical success, adverse events, reintervention, and overall survival were assessed.</p><p><strong>Results: </strong>The technical success rate of EUS-HGS was 92% (123/134). A total of 80 patients with technical success (40 FCMS, 40 PCMS) were selected after propensity score matching. The two groups showed similar rates of clinical success (90% vs. 88%; P = 0.999), early adverse events (15% vs. 20%; P = 0.556), late adverse events (18% vs. 33%; P = 0.121), reintervention (20% vs. 38%; P = 0.084), and median overall survival (4.1 months [95% confidence interval (CI) 2.6-5.5] vs. 3.8 months [95% CI 1.9-5.7]; P = 0.609). During follow-up, the FCMS group showed higher patency rates (85% vs. 60% at 6 months; 76% vs. 43% at 12 months; P = 0.030).</p><p><strong>Conclusions: </strong>FCMS and PCMS for EUS-HGS in patients with unresectable MBO showed similar rates of clinical success, as well as early and late adverse events. However, the FCMS group showed a higher cumulative stent patency rate compared to the PCMS group.</p>","PeriodicalId":72813,"journal":{"name":"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/den.14952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) using a fully covered metal stent (FCMS) or partially covered metal stent (PCMS) is performed to manage unresectable malignant biliary obstruction (MBO) following unsuccessful endoscopic retrograde cholangiopancreatography. This study aimed to compare FCMS and PCMS for EUS-HGS in patients with MBO.

Methods: We reviewed the EUS database to analyze consecutive patients with MBO who underwent EUS-HGS between November 2017 and March 2023. We performed a 1:1 matching using propensity score matching based on potential confounding factors. Stent patency, technical success, clinical success, adverse events, reintervention, and overall survival were assessed.

Results: The technical success rate of EUS-HGS was 92% (123/134). A total of 80 patients with technical success (40 FCMS, 40 PCMS) were selected after propensity score matching. The two groups showed similar rates of clinical success (90% vs. 88%; P = 0.999), early adverse events (15% vs. 20%; P = 0.556), late adverse events (18% vs. 33%; P = 0.121), reintervention (20% vs. 38%; P = 0.084), and median overall survival (4.1 months [95% confidence interval (CI) 2.6-5.5] vs. 3.8 months [95% CI 1.9-5.7]; P = 0.609). During follow-up, the FCMS group showed higher patency rates (85% vs. 60% at 6 months; 76% vs. 43% at 12 months; P = 0.030).

Conclusions: FCMS and PCMS for EUS-HGS in patients with unresectable MBO showed similar rates of clinical success, as well as early and late adverse events. However, the FCMS group showed a higher cumulative stent patency rate compared to the PCMS group.

在内镜超声引导下进行肝胃造口术治疗恶性胆道梗阻时,全覆盖金属支架与部分覆盖金属支架的比较(附视频)。
背景:使用全覆盖金属支架(FCMS)或部分覆盖金属支架(PCMS)进行内镜超声引导肝胃造口术(EUS-HGS),可治疗内镜逆行胰胆管造影术失败后无法切除的恶性胆道梗阻(MBO)。本研究旨在比较 FCMS 和 PCMS 在 MBO 患者 EUS-HGS 中的应用:我们回顾了 EUS 数据库,分析了在 2017 年 11 月至 2023 年 3 月期间接受 EUS-HGS 的连续 MBO 患者。我们根据潜在的混杂因素,使用倾向得分匹配法进行了 1:1 匹配。对支架通畅率、技术成功率、临床成功率、不良事件、再介入和总生存率进行了评估:EUS-HGS的技术成功率为92%(123/134)。经过倾向评分匹配后,共挑选出 80 名技术成功的患者(40 名 FCMS,40 名 PCMS)。两组患者的临床成功率(90% 对 88%;P = 0.999)、早期不良事件发生率(15% 对 20%;P = 0.556)、晚期不良事件发生率(18% 对 33%;P = 0.121)、再介入率(20% 对 38%;P = 0.084)和中位总生存期(4.1 个月 [95% 置信区间 (CI) 2.6-5.5] 对 3.8 个月 [95% CI 1.9-5.7] ;P = 0.609)相似。随访期间,FCMS 组的通畅率更高(6 个月时为 85% vs. 60%;12 个月时为 76% vs. 43%;P = 0.030):结论:FCMS 和 PCMS 用于不可切除的 MBO 患者的 EUS-HGS 临床成功率以及早期和晚期不良反应相似。然而,与 PCMS 组相比,FCMS 组的累积支架通畅率更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信